The new 15,775m² facility is designed to produce devices and technologies that support improved medication safety within healthcare settings and is expected to create 500 new jobs during the next two years
BD opens new manufacturing facility. (Credit: Laurynas Mereckas on Unsplash)
US-based medical device company BD has opened a new medication management manufacturing facility in Tijuana, Mexico, which involved a $38.6m investment.
The new 15,775m2 facility is designed to produce devices and technologies that help improve medication safety within healthcare settings.
It is expected to create 500 new jobs during the next two years, with 75 new jobs expected during Phase one.
Phase one of the facility will focus on manufacturing automated dispensing cabinets used by healthcare professionals.
The medication management devices will be distributed across North American, European, African, and Asian countries, said BD.
BD vice president and Mexico, the Caribbean and Central America general director Julio Duclos said: “Our new facility in Tijuana is BD’s 12th manufacturing plant in Mexico and is a testament to our commitment to Mexico and the strong relationship we’ve built in communities across the country over the past 65 years.
“The 17,000 BD employees in Mexico are focused on producing high-quality medical devices that are used by health care providers and patients around the world. We look forward to continuing to grow in Mexico.”
BD said that its decision to expand in Tijuana is part of its four-year strategic plan to invest $1.2bn to upgrade its technology and production capacity worldwide.
The company aims to obtain the ISO 14001:2015 Environmental Management and Risk, Safe Company, and ISO 45001 Occupational Health and Safety Management Systems certification.
In addition, it intends to secure Clean Industry, Smoke-Free Company C-TPAT, BSI ISO 13485, MDSAP, CSA and Intertek certifications.
BD medication management solutions president Puneet Sarin said: “BD has been a leader in leveraging the cross-border efficiencies that are created in the Tijuana-San Diego region, and this new plant will continue to help BD simplify our operations by combining a manufacturing site, a distribution centre and the means to deliver products to the end customer in one place.
“By simplifying our operations, BD can continue to focus on advancing the world of health by developing new technologies that improve how medications are stored, dispensed and administered to help ensure optimal outcomes.”
In September this year, BD unveiled its new cloud-based software solution, BD Research Cloud, intended to streamline the cytometry workflow.